MONECO Advisors LLC Has $104,000 Holdings in Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

MONECO Advisors LLC lessened its position in Walgreens Boots Alliance, Inc. (NASDAQ:WBA) by 24.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 11,156 shares of the pharmacy operator’s stock after selling 3,708 shares during the period. MONECO Advisors LLC’s holdings in Walgreens Boots Alliance were worth $104,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. First Financial Corp IN grew its stake in Walgreens Boots Alliance by 49.2% in the fourth quarter. First Financial Corp IN now owns 2,685 shares of the pharmacy operator’s stock valued at $25,000 after acquiring an additional 885 shares during the period. Golden State Wealth Management LLC acquired a new stake in Walgreens Boots Alliance in the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC acquired a new stake in Walgreens Boots Alliance in the fourth quarter valued at approximately $28,000. TD Private Client Wealth LLC lifted its holdings in shares of Walgreens Boots Alliance by 8,670.3% in the third quarter. TD Private Client Wealth LLC now owns 3,245 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 3,208 shares in the last quarter. Finally, Sentry Investment Management LLC bought a new position in shares of Walgreens Boots Alliance in the third quarter valued at approximately $30,000. Institutional investors and hedge funds own 58.59% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on WBA. Bank of America raised their target price on Walgreens Boots Alliance from $7.50 to $8.50 and gave the company an “underperform” rating in a report on Monday, January 13th. Truist Financial dropped their target price on Walgreens Boots Alliance from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Friday, January 31st. Evercore ISI raised their target price on Walgreens Boots Alliance from $9.00 to $12.00 and gave the company an “in-line” rating in a report on Monday, January 13th. Royal Bank of Canada raised their target price on Walgreens Boots Alliance from $9.00 to $12.00 and gave the company a “sector perform” rating in a report on Wednesday, January 15th. Finally, Wolfe Research upgraded Walgreens Boots Alliance to a “hold” rating in a report on Monday. Three analysts have rated the stock with a sell rating, ten have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Walgreens Boots Alliance presently has an average rating of “Hold” and a consensus price target of $12.63.

Walgreens Boots Alliance Stock Performance

Shares of WBA opened at $11.38 on Wednesday. The firm has a market cap of $9.83 billion, a PE ratio of -1.11, a PEG ratio of 1.31 and a beta of 0.64. The stock’s fifty day moving average price is $10.41 and its two-hundred day moving average price is $9.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 0.64 and a quick ratio of 0.30. Walgreens Boots Alliance, Inc. has a 1 year low of $8.08 and a 1 year high of $22.05.

Walgreens Boots Alliance (NASDAQ:WBA) last issued its earnings results on Friday, January 10th. The pharmacy operator reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.13. The firm had revenue of $39.50 billion for the quarter, compared to analyst estimates of $37.40 billion. Walgreens Boots Alliance had a positive return on equity of 17.61% and a negative net margin of 5.87%. The business’s revenue was up 7.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 earnings per share. On average, equities research analysts forecast that Walgreens Boots Alliance, Inc. will post 1.6 EPS for the current year.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.